Donna E. Reece
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Donna E. Reece has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Suzanne Trudel
Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada
9 shared publications - Christine I. Chen
University of Toronto Toronto Ontario Canada
8 shared publications - Esther Masih-Khan
Princess Margaret Cancer Centre 1 Division of Medical Oncology and Hematology Toronto, Canada
8 shared publications - Vishal Kukreti
Princess Margaret Cancer Centre 1 Division of Medical Oncology and Hematology Toronto, Canada
8 shared publications - Sita Bhella
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
7 shared publications - Alexander Keith Stewart
Princess Margaret Cancer Centre 1 Division of Medical Oncology and Hematology Toronto, Canada
6 shared publications
Latest Publications
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7586-7596
Teclistamab and daratumumab immune-based doublet therapy for relapsed/refractory multiple myeloma: the TRIMM-2 study
Teclistamab is the first approved B-cell maturation antigen × CD3 bispecific antibody with weight-based dosing for triple-class–exposed relapsed/refractory multiple myeloma (RRMM). We evaluated the safety and efficacy of teclistamab combined with daratumumab in the phase 1b TRIMM-2 study. Eligible patients had RRMM (≥3 previous lines of therapy [pLOT] or with disease double-refractory to a proteasome inhibitor and immunomodulatory drug); anti-CD38 exposure was permitted. Patients received subcutaneous daratumumab per approved schedule plus weight-based or fixed-dose subcutaneous teclistamab. The primary end point was safety; secondary end points included overall response rate (ORR) and duration of response (DOR). Progression-free survival (PFS) was exploratory. Sixty-one patients received weight-based, recommended phase 2 doses (RP2D; teclistamab 1.5 mg/kg weekly or 3.0 mg/kg every other week); median number of pLOTs was 5 (range, 1-14). Median follow-up was 12.0 months. Common treatment-emergent adverse events (TEAEs) included infections, cytokine release syndrome, neutropenia, and anemia; grade 3/4 TEAEs occurred in 93.4%; 7 died of TEAEs. Any-grade infections occurred in 82.0% (grade 3/4 [maximum toxicity], 45.9%; grade 5, 8.2%). No dose-limiting toxicities occurred. ORR was 68.9% (complete response or better, 44.3%); median DOR was not reached. Median PFS was 26.3 months. A cohort exploring fixed-dose teclistamab (100-300 mg) ended prematurely after a safety signal for fatal infections was identified; out of an abundance of caution, all patients were switched to weight-based dosing. In conclusion, the fully immune-based combination of weight-based RP2D teclistamab plus daratumumab demonstrated deep and durable responses, with a well-characterized safety profile. Results highlight the importance of infection management, including early immunoglobulin replacement. This trial was registered at www.clinicaltrials.gov as NCT04108195.
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7586-7596
Teclistamab and daratumumab immune-based doublet therapy for relapsed/refractory multiple myeloma: the TRIMM-2 study
Teclistamab is the first approved B-cell maturation antigen × CD3 bispecific antibody with weight-based dosing for triple-class–exposed relapsed/refractory multiple myeloma (RRMM). We evaluated the safety and efficacy of teclistamab combined with daratumumab in the phase 1b TRIMM-2 study. Eligible patients had RRMM (≥3 previous lines of therapy [pLOT] or with disease double-refractory to a proteasome inhibitor and immunomodulatory drug); anti-CD38 exposure was permitted. Patients received subcutaneous daratumumab per approved schedule plus weight-based or fixed-dose subcutaneous teclistamab. The primary end point was safety; secondary end points included overall response rate (ORR) and duration of response (DOR). Progression-free survival (PFS) was exploratory. Sixty-one patients received weight-based, recommended phase 2 doses (RP2D; teclistamab 1.5 mg/kg weekly or 3.0 mg/kg every other week); median number of pLOTs was 5 (range, 1-14). Median follow-up was 12.0 months. Common treatment-emergent adverse events (TEAEs) included infections, cytokine release syndrome, neutropenia, and anemia; grade 3/4 TEAEs occurred in 93.4%; 7 died of TEAEs. Any-grade infections occurred in 82.0% (grade 3/4 [maximum toxicity], 45.9%; grade 5, 8.2%). No dose-limiting toxicities occurred. ORR was 68.9% (complete response or better, 44.3%); median DOR was not reached. Median PFS was 26.3 months. A cohort exploring fixed-dose teclistamab (100-300 mg) ended prematurely after a safety signal for fatal infections was identified; out of an abundance of caution, all patients were switched to weight-based dosing. In conclusion, the fully immune-based combination of weight-based RP2D teclistamab plus daratumumab demonstrated deep and durable responses, with a well-characterized safety profile. Results highlight the importance of infection management, including early immunoglobulin replacement. This trial was registered at www.clinicaltrials.gov as NCT04108195.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma
Overall survival after teclistamab comparing a) non-Hi-MM vs Hi-MM pre-teclistamab in the training cohort, b) non-Hi-MM vs Hi-MM pre-teclistamab in the validation cohort, c) by disease burden pre-teclistamab and receipt of chemotherapy in the training cohort. The log-rank test was used to compare overall survival.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma
Overall survival after teclistamab comparing a) non-Hi-MM vs Hi-MM pre-teclistamab in the training cohort, b) non-Hi-MM vs Hi-MM pre-teclistamab in the validation cohort, c) by disease burden pre-teclistamab and receipt of chemotherapy in the training cohort. The log-rank test was used to compare overall survival.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S3 from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma
Supplementary Tables demonstrating correlates of overall response (Supplementary Table 1), progression-free survival (Supplementary Table 2), and overall survival (Supplementary Table 3) in the training and validation cohorts
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S3 from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma
Supplementary Tables demonstrating correlates of overall response (Supplementary Table 1), progression-free survival (Supplementary Table 2), and overall survival (Supplementary Table 3) in the training and validation cohorts
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma
Patient disposition in the training cohort with respect to Hi-MM status at the time of debulking chemotherapy and at the time of teclistamab administration.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma
Patient disposition in the training cohort with respect to Hi-MM status at the time of debulking chemotherapy and at the time of teclistamab administration.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma
Bispecific antibodies have revolutionized the treatment of multiple myeloma; however, primary treatment failure occurs in 30% to 40% of patients. In this study, we analyzed correlates of response to teclistamab and strategies to overcome primary resistance. Across two independent cohorts (n = 90), we developed the high risk of primary resistance (Hi-MM) variable, defined by extramedullary disease, plasma cell leukemia, bone marrow plasmacytosis ≥50%, or transfusion within 30 days, as a composite correlate of nonresponse. Patients without Hi-MM had overall response rates of 84% to 96% (vs. 20%–40% with Hi-MM) and significantly superior progression-free survival (P < 0.001) and overall survival (P < 0.001). Debulking chemotherapy was utilized in 19 patients; 79% then responded to teclistamab, including 100% who no longer had Hi-MM. All four patients who were primary refractory to a BCMA bispecific immediately prior to debulking then achieved deep responses to teclistamab. In conclusion, simple clinical parameters correlate with response to teclistamab, whereas debulking chemotherapy can overcome Hi-MM and successfully bridge patients to teclistamab or salvage nonresponders.Significance:A clinically assessable composite variable, Hi-MM, identifies patients who may benefit from debulking chemotherapy prior to teclistamab. By treating patients at a time of low disease burden or using debulking chemotherapy for those with a high risk of resistance, nearly all patients can benefit from the deep and durable remissions induced by teclistamab.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma
Bispecific antibodies have revolutionized the treatment of multiple myeloma; however, primary treatment failure occurs in 30% to 40% of patients. In this study, we analyzed correlates of response to teclistamab and strategies to overcome primary resistance. Across two independent cohorts (n = 90), we developed the high risk of primary resistance (Hi-MM) variable, defined by extramedullary disease, plasma cell leukemia, bone marrow plasmacytosis ≥50%, or transfusion within 30 days, as a composite correlate of nonresponse. Patients without Hi-MM had overall response rates of 84% to 96% (vs. 20%–40% with Hi-MM) and significantly superior progression-free survival (P < 0.001) and overall survival (P < 0.001). Debulking chemotherapy was utilized in 19 patients; 79% then responded to teclistamab, including 100% who no longer had Hi-MM. All four patients who were primary refractory to a BCMA bispecific immediately prior to debulking then achieved deep responses to teclistamab. In conclusion, simple clinical parameters correlate with response to teclistamab, whereas debulking chemotherapy can overcome Hi-MM and successfully bridge patients to teclistamab or salvage nonresponders.Significance:A clinically assessable composite variable, Hi-MM, identifies patients who may benefit from debulking chemotherapy prior to teclistamab. By treating patients at a time of low disease burden or using debulking chemotherapy for those with a high risk of resistance, nearly all patients can benefit from the deep and durable remissions induced by teclistamab.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma
Progression-free survival after teclistamab comparing a) non-Hi-MM vs Hi-MM pre-teclistamab in the training cohort, b) non-Hi-MM vs Hi-MM pre-teclistamab in the validation cohort, c) by disease burden pre-teclistamab and receipt of chemotherapy in the training cohort. The log-rank test was used to compare progression-free survival.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma
Progression-free survival after teclistamab comparing a) non-Hi-MM vs Hi-MM pre-teclistamab in the training cohort, b) non-Hi-MM vs Hi-MM pre-teclistamab in the validation cohort, c) by disease burden pre-teclistamab and receipt of chemotherapy in the training cohort. The log-rank test was used to compare progression-free survival.
- Open Access
- 29 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (9) , 2890-2903
Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias
Plasma cell dyscrasias (PCD) are a group of hematologic disorders associated with immune dysfunction from underlying disease and/or treatment. With the continued circulation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), optimizing and maintaining durable protection in this vulnerable population through vaccination remains important. A prospective cohort study was conducted between August 2021 and January 2023 across 12 sites in Canada to evaluate humoral immunity to COVID-19 vaccination in participants with hematologic malignancies. Participants were monitored longitudinally, and finger-prick dried blood spot cards were obtained at specific intervals based on vaccination. Serum antibodies against SARS-CoV-2 proteins after the third, fourth, and fifth dose were measured by high-throughput enzyme-linked immunosorbent assay. Differences in antispike (anti-S) seropositivity by vaccine dose number and clinical risk factors were analyzed by logistic regression. A total of 262 unique participants with 983 samples were included for analysis, among which 66% were diagnosed with PCD. Analysis of the predicted probability of immunity showed consistently higher proportions of participants with PCD with vaccine (anti-S) immunity compared with those with infection-derived (antinucleocapsid) immunity throughout the study. Although vaccine responses appeared to wane 6 months after dose 3 and, to a lesser extent, after dose 4, subsequent doses cumulatively increased anti-S immunity. Seropositivity decreased with anti-CD38 therapy and older age, although the receipt of additional vaccine doses significantly improved anti-S immunity. Overall, this study demonstrated that the third and subsequent COVID-19 vaccine doses could safely improve humoral immunity in participants with PCD. Although anti-CD38 therapy and age reduced seropositivity, antibody responses could still be enhanced with vaccine doses beyond the primary 3-dose series.
- 29 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (9) , 2890-2903
Open AccessImmunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias
Plasma cell dyscrasias (PCD) are a group of hematologic disorders associated with immune dysfunction from underlying disease and/or treatment. With the continued circulation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), optimizing and maintaining durable protection in this vulnerable population through vaccination remains important. A prospective cohort study was conducted between August 2021 and January 2023 across 12 sites in Canada to evaluate humoral immunity to COVID-19 vaccination in participants with hematologic malignancies. Participants were monitored longitudinally, and finger-prick dried blood spot cards were obtained at specific intervals based on vaccination. Serum antibodies against SARS-CoV-2 proteins after the third, fourth, and fifth dose were measured by high-throughput enzyme-linked immunosorbent assay. Differences in antispike (anti-S) seropositivity by vaccine dose number and clinical risk factors were analyzed by logistic regression. A total of 262 unique participants with 983 samples were included for analysis, among which 66% were diagnosed with PCD. Analysis of the predicted probability of immunity showed consistently higher proportions of participants with PCD with vaccine (anti-S) immunity compared with those with infection-derived (antinucleocapsid) immunity throughout the study. Although vaccine responses appeared to wane 6 months after dose 3 and, to a lesser extent, after dose 4, subsequent doses cumulatively increased anti-S immunity. Seropositivity decreased with anti-CD38 therapy and older age, although the receipt of additional vaccine doses significantly improved anti-S immunity. Overall, this study demonstrated that the third and subsequent COVID-19 vaccine doses could safely improve humoral immunity in participants with PCD. Although anti-CD38 therapy and age reduced seropositivity, antibody responses could still be enhanced with vaccine doses beyond the primary 3-dose series.
- Open Access
- 10 March 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (3) , 394-402
Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma
Bispecific antibodies have revolutionized the treatment of multiple myeloma; however, primary treatment failure occurs in 30% to 40% of patients. In this study, we analyzed correlates of response to teclistamab and strategies to overcome primary resistance. Across two independent cohorts (n = 90), we developed the high risk of primary resistance (Hi-MM) variable, defined by extramedullary disease, plasma cell leukemia, bone marrow plasmacytosis ≥50%, or transfusion within 30 days, as a composite correlate of nonresponse. Patients without Hi-MM had overall response rates of 84% to 96% (vs. 20%–40% with Hi-MM) and significantly superior progression-free survival (P < 0.001) and overall survival (P < 0.001). Debulking chemotherapy was utilized in 19 patients; 79% then responded to teclistamab, including 100% who no longer had Hi-MM. All four patients who were primary refractory to a BCMA bispecific immediately prior to debulking then achieved deep responses to teclistamab. In conclusion, simple clinical parameters correlate with response to teclistamab, whereas debulking chemotherapy can overcome Hi-MM and successfully bridge patients to teclistamab or salvage nonresponders. Significance: A clinically assessable composite variable, Hi-MM, identifies patients who may benefit from debulking chemotherapy prior to teclistamab. By treating patients at a time of low disease burden or using debulking chemotherapy for those with a high risk of resistance, nearly all patients can benefit from the deep and durable remissions induced by teclistamab.
- 10 March 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (3) , 394-402
Open AccessDebulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma
Bispecific antibodies have revolutionized the treatment of multiple myeloma; however, primary treatment failure occurs in 30% to 40% of patients. In this study, we analyzed correlates of response to teclistamab and strategies to overcome primary resistance. Across two independent cohorts (n = 90), we developed the high risk of primary resistance (Hi-MM) variable, defined by extramedullary disease, plasma cell leukemia, bone marrow plasmacytosis ≥50%, or transfusion within 30 days, as a composite correlate of nonresponse. Patients without Hi-MM had overall response rates of 84% to 96% (vs. 20%–40% with Hi-MM) and significantly superior progression-free survival (P < 0.001) and overall survival (P < 0.001). Debulking chemotherapy was utilized in 19 patients; 79% then responded to teclistamab, including 100% who no longer had Hi-MM. All four patients who were primary refractory to a BCMA bispecific immediately prior to debulking then achieved deep responses to teclistamab. In conclusion, simple clinical parameters correlate with response to teclistamab, whereas debulking chemotherapy can overcome Hi-MM and successfully bridge patients to teclistamab or salvage nonresponders. Significance: A clinically assessable composite variable, Hi-MM, identifies patients who may benefit from debulking chemotherapy prior to teclistamab. By treating patients at a time of low disease burden or using debulking chemotherapy for those with a high risk of resistance, nearly all patients can benefit from the deep and durable remissions induced by teclistamab.
- Open Access
- 10 March 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (2)
Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report
- 10 March 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (2)
Open AccessReal-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report
- 9 October 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (15) , 1741-1742
Mel200 or BuMel conditioning in myeloma: is there a winner?
- 9 October 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (15) , 1741-1742
Mel200 or BuMel conditioning in myeloma: is there a winner?